The therapeutic purpose of Co-Dalnessa is centered on achieving and maintaining stable blood pressure control, and is considered relevant in challenging clinical contexts. This medicine is commonly used in the treatment of high blood pressure (hypertension).

The medication is generally applied in conditions involving Grade 2 or 3 Hypertension and in patients with a High Cardiovascular Risk, such as those with Type 2 Diabetes Mellitus. It is also relevant as a Substitution Therapy to simplify treatment for those whose blood pressure is already well-managed on the three individual components. The primary benefit supports a focused reduction in elevated blood pressure, supporting the easing of physiological strain associated with high blood pressure.

“The single-pill formulation supports patients in consistently managing a chronic condition, a factor relevant to maintaining well-being over time.”

This combination helps maintain a sustained 24-hour control and may assist in lowering the associated risk of severe cardiovascular events like stroke and heart attack. This simplification eases the overall burden of a complex daily regimen, assisting with routine administration of the medication.

---

Quick Fact: Support in Managing Chronic Physiological Strain Co-Dalnessa is considered relevant in conditions where uncontrolled Essential Hypertension is associated with chronic physiological stress on the cardiovascular system, requiring multi-agent stabilization and Target Organ Protection.

Who Can and Cannot Use Co-Dalnessa?

This medicine's eligibility is strictly defined by regulatory authorities based on population characteristics and specific health conditions. The following information reflects official criteria for use.

Allowed Population

Co-Dalnessa is approved for use only in adult patients (18 years of age). Its use is typically limited to substitution therapy for adults whose high blood pressure is already well-controlled on the three individual active components taken separately.

Absolute Contraindications (Must Not Use)

Use is strictly contraindicated for several populations, including:

• Patients with a history of angioedema (swelling) or a known hypersensitivity to any component or related drug class.
• Individuals with severe renal impairment (kidney disease) or severe hepatic impairment (liver disease).
• Women in the second and third trimesters of pregnancy or who are breastfeeding.
• Patients diagnosed with Cardiogenic Shock or Left Ventricular Outflow Tract Obstruction.
• Patients concurrently taking the combination medicine Sacubitril/Valsartan.

Population Restrictions and Limitations

Use in children and adolescents ( < 18 years) is not recommended as safety and effectiveness have not been established. High-dose formulations are specifically contraindicated in patients with moderate renal impairment. Use is generally not recommended during the first trimester of pregnancy.

The interaction profile for Co-Dalnessa (Amlodipine, Indapamide, Perindopril) is formally documented around specific pharmacokinetic and pharmacodynamic constraints, strictly based on regulatory labeling.

Contraindicated Combinations and Timing Rules

Co-administration with Sacubitril/Valsartan is contraindicated due to the Perindopril component, as it carries a high risk of angioedema. A mandatory 36-hour separation period must be observed when initiating either Co-Dalnessa or Sacubitril/Valsartan. The use of Aliskiren is also contraindicated in patients with established Diabetes Mellitus or defined Renal Impairment (GFR < 60 mL/ min/1.73 m^2).

---

Metabolism, Exposure, and Electrolyte Risk

The Amlodipine component undergoes pharmacokinetic interaction via the CYP3A4 pathway. Strong CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir) are documented to increase Amlodipine plasma concentration. Conversely, CYP3A4 inducers (e.g., Rifampicin, St. John's Wort) may reduce it. This increase in exposure is also why the dose of co-administered Simvastatin must be restricted to 20 mg daily. Pharmacodynamically, co-use with Potassium-sparing diuretics or Potassium supplements increases the risk of Hyperkalaemia. The combination with Lithium is not recommended due to its potential for increased toxicity. NSAIDs may diminish the antihypertensive effect and increase adverse renal effects.

Dual Modulation of Arterial Tone and Resistance

This mechanism is defined by Amlodipine's prolonged functional blockade of L-Type Calcium Channels ( Ca v1.2) in peripheral arterial smooth muscle cells. This action interrupts the influx of calcium ions, which are essential for muscle contraction, initiating widespread vasodilation and resulting in a reduction of Total Peripheral Resistance (TPR).

Inhibition of the Hormonal Constriction Cascade (RAAS)

The component Perindopril acts via its metabolite as a competitive inhibitor of the Angiotensin-Converting Enzyme (ACE). This suppresses the formation of Angiotensin II, a key vasoconstricting hormone, thereby dampening systemic signals for vessel tightening and salt retention, and modulating the neuro-hormonal feedback loops involved in arterial pressure regulation.

Regulation of Circulating Volume and Electrolytes

The third action involves Indapamide's inhibition of the Na^+/ Cl^- Cotransporter in the kidney's distal convoluted tubule. This leads to increased renal excretion of salt and water. This pathway results in a reduction of extracellular fluid volume, which complements the vascular relaxation effects and contributes to systemic volume changes.

Pharmacological Synergy

The combination achieves coordinated modulation across multiple physiological axes by simultaneously engaging three independent pathways: vessel tone, hormonal control, and fluid volume. Mechanistically, this provides a homeostatic counterbalance, where the volume-reducing effects are moderated by the ACE inhibitor's ability to minimize potassium loss.

How to Use Co-Dalnessa: Official Administration Guidelines

Co-Dalnessa is an oral medication, formulated as a single film-coated tablet that is intended for the long-term management of essential hypertension. The principles of its use are established to ensure proper administration.

---

Official Dosing and Regimen

The standard pattern of administration is once daily, taken as a single dose. The maximum recommended daily dose is the highest available strength, typically 10 mg/2.5 mg/10 mg (Perindopril/Indapamide/Amlodipine).

Crucially, this fixed-dose combination (FDC) is not suitable for initiating treatment. Its role is restricted to substitution therapy in adult patients whose blood pressure is already well-controlled by taking the three individual components simultaneously at the same dose levels.

---

Administration Conditions and Timing

Instruction Entity	Statement
Route of administration	The medication is taken by the oral route.
Timing in relation to meals	The tablet must be taken in the morning and before a meal.
Preparation requirements	The tablet should be swallowed whole with a glass of water.

---

Procedural Constraints and Special Populations

If a dose adjustment is necessary, the treating professional must perform the titration using the individual components rather than the FDC tablet. The FDC should not be used in children or adolescents, as its safety and efficacy have not been established in these age groups. If a dose is missed, the recommended procedure is to skip the missed dose and take the next dose at the usual time the following day; taking a double dose to compensate is not advised.

Research evidence / Overview of Studies for Co-Dalnessa

Evidence for Use in Essential and Uncontrolled High Blood Pressure

The use of this triple fixed-dose combination was studied for adults diagnosed with essential high blood pressure, including those whose blood pressure was previously uncontrolled despite taking other single or dual-drug regimens. Studies conducted were primarily Randomized Controlled Trials (RCTs) and open-label prospective trials that monitored patient responses over short-term periods, typically up to six months.

The research outcomes examined included measurements related to physiological strain, focusing on changes in blood pressure levels. Findings describe patterns observed in the studies where participants experienced a measured decrease in both systolic and diastolic blood pressure. Research evaluated whether the single-pill combination was associated with similar blood pressure measurements when compared to taking the three components as separate pills.

Evidence in High Cardiovascular Risk Populations

This area of research was studied for adults with hypertension who also presented with high cardiovascular risk, such as those with Type 2 Diabetes Mellitus. Studies included large observational cohorts that followed patients over longer periods. Findings indicate that this fixed triple combination was associated with measured changes in certain physiological markers, such as blood vessel stiffness and heart muscle mass.

Research has been studied for the combination's role as a Substitution Therapy. Findings describe patterns observed in the studies where the proportion of patients taking their medication as prescribed was observed to be higher when using the single-pill combination compared to taking the free-drug equivalent.

What Remains Uncertain and Areas for Future Research

Evidence is limited for the long-term impact of this specific fixed-dose combination on major cardiovascular events over several years. The evidence base includes extensive studies on the three active ingredients, particularly the component combination of Perindopril and Indapamide, which was observed in trials with long follow-up durations. Data for certain groups remain insufficient, and the results apply only to the populations studied. This means that evidence on long-term outcomes related to major events is not fully established specifically for the single-pill formulation.

Key Studies & References Assessment Report on Amlodipine, Indapamide, Perindopril fixed combination tablet (Co-Dalnessa Regulatory Document)

Common questions about Co-Dalnessa (FAQ)

---

Q: Is Co-Dalnessa the same as other medicines for the same condition?

Co-Dalnessa is a three-component fixed-dose combination, which is one type of medicine used to manage high blood pressure. According to official documents, its primary role is substitution therapy for adults whose blood pressure is already controlled by taking the three individual components separately. Other medicines for high blood pressure may contain fewer components or belong to different drug classes.

Q: Why do doctors prescribe Co-Dalnessa instead of another drug?

Official documentation describes Co-Dalnessa's use as substitution therapy when an adult patient’s high blood pressure is already well-controlled on the three individual active components. Research evidence themes indicate that using a single-pill fixed-dose combination (FDC) was associated with higher rates of patients taking the medication as prescribed, compared to taking the free-drug equivalent.

Q: How quickly should I expect to notice any effects from Co-Dalnessa?

Regulatory data generally focuses on the medicine's effectiveness in maintaining a consistent reduction in blood pressure over time rather than immediate effects. Because the medicine is a once-daily formulation, its components are intended to maintain a continuous effect throughout the 24-hour dosing interval.

Q: How long does a dose of Co-Dalnessa last in the body?

The medicine is intended for once-daily use to manage high blood pressure continuously. Official pharmacokinetic data indicates that the active substances have elimination half-lives that support the 24-hour dosing schedule.

Q: Do food or drink affect how Co-Dalnessa works?

Yes, official instructions state that the tablet must be taken in the morning and before a meal. Regulatory documents state that food is known to decrease the conversion of Perindopril to its active form, Perindoprilat, reducing its absorption.

Q: Is it safe to drink alcohol while taking Co-Dalnessa?

Official warnings note that alcohol may increase the risk of hypotension (low blood pressure), which is the blood pressure-lowering effect of the medicine. This potential for enhanced effect could lead to symptoms such as dizziness or feeling light-headed.

Q: Are there any known interactions between Co-Dalnessa and herbal supplements?

Official documentation specifically describes an interaction risk with St. John’s Wort, which is a known herbal product. According to the regulatory information, St. John’s Wort may cause the plasma concentration of the Amlodipine component to be reduced.

Q: Can I take Co-Dalnessa if I have high blood pressure?

Co-Dalnessa is officially approved for the management of essential high blood pressure (hypertension) in adult patients. Its use is strictly defined in official documents as substitution therapy for adults whose blood pressure is already well-controlled on the three individual active components taken separately.

Q: Does Co-Dalnessa interact with grapefruit?

Regulatory documents state that co-administration with strong CYP3A4 inhibitors can increase the plasma concentration of the Amlodipine component. Grapefruit is widely discussed as a CYP3A4 inhibitor, which is the enzyme system cited for the interaction risk.

Q: Can Co-Dalnessa affect my ability to drive or operate machinery?

Official information states that the medicine may cause adverse reactions such as dizziness, fatigue, or headache, especially when treatment begins. Official guidance states that patients must be aware of these potential effects before driving or operating machinery.

Q: What happens if I stop taking Co-Dalnessa suddenly?

Treatment for high blood pressure is typically long-term management. Official regulatory information states that consultation with a healthcare professional is necessary before stopping use of the medicine.

Q: Does Co-Dalnessa interfere with laboratory test results?

Yes, official documentation lists potential changes in certain laboratory parameters as possible adverse reactions. These include changes in creatinine, potassium (hyperkalaemia), and sodium (hyponatraemia) levels, which require monitoring.

Q: Does the evidence for Co-Dalnessa include long-term studies?

The overall evidence base includes extensive long-term studies on the component combination of Perindopril and Indapamide. However, the evidence base includes limited data for the long-term impact of the specific single-pill fixed-dose combination on major cardiovascular events over several years.

Q: How is Co-Dalnessa packaged and dispensed?

According to regulatory sources, the medicine is typically dispensed as tablets in blister packs, which are placed inside a cardboard box. The packaging is designed to protect the tablets from exposure to light and moisture.

Q: How is Co-Dalnessa eliminated from the body?

The three components are eliminated via different routes. Perindoprilat is mainly eliminated through the urine, while Indapamide is eliminated mainly in the urine and faeces. Amlodipine is largely converted to inactive substances before being eliminated in the urine.

Q: Does Co-Dalnessa need to be kept refrigerated?

No, official storage instructions state that the medicine should be stored below 30°C. It must be kept in the original container, with the container tightly closed, to protect the tablets from light and moisture. Refrigeration is not required.

Q: Can Co-Dalnessa interact with vitamins or minerals?

Official regulatory documents specifically warn about a risk of interaction with potassium supplements or potassium-containing salt substitutes. Co-use may increase the risk of hyperkalaemia (high potassium) due to the Perindopril component.

Q: Is it possible to be allergic to an ingredient in Co-Dalnessa?

The medicine is contraindicated for individuals with a known hypersensitivity (severe allergic reaction) to any of its components, non-active ingredients, or to drugs in related classes, such as ACE inhibitors.

Q: Does taking Co-Dalnessa require regular blood tests?

Official regulatory warnings state that the combined effects of the medicine's components necessitate regular medical follow-up. This medical follow-up involves the monitoring of creatinine (a measure of kidney function) and potassium levels.

Q: Is Co-Dalnessa generally well-tolerated according to official reports?

Adverse reactions are classified by their frequency in official documents. The most common side effects, such as dizziness and headache, are described as affecting up to 1 in 10 people and are noted as being more frequent when treatment begins.

Q: Are there different strengths of Co-Dalnessa available?

Yes. Official regulatory labeling for the medicine includes multiple strengths of the fixed-dose combination. These variations relate to the amount of each of the three active ingredients (Perindopril, Indapamide, and Amlodipine) in each tablet.

Q: Do official sources describe Co-Dalnessa as causing weight gain?

Official regulatory documents list 'weight increase or decrease' as a possible uncommon adverse reaction. This is described as affecting up to 1 in 100 people who use the medicine.

Q: Can I use Co-Dalnessa if I am vegetarian or have dietary restrictions?

Official documentation includes a list of the non-active ingredients, or excipients, in the tablet. Individuals with specific dietary restrictions may need to have the composition reviewed.

Q: Are there any warnings about Co-Dalnessa and exposure to sunlight?

Yes. Regulatory documents state that photosensitivity reactions (increased skin sensitivity to sunlight) have been reported with the Indapamide component. Patients are advised to take necessary measures to protect themselves from sun exposure.

How to Store and Dispose of Co-Dalnessa

Co-Dalnessa must be stored strictly according to the conditions specified in official regulatory labeling to maintain the integrity of its triple-component formulation.

Storage Requirements

Storage Element	Requirement
Temperature	Store below 30°C.
Protection	Keep in the original container to protect it from both moisture and light.
Container Rule	The container must be kept tightly closed.
Shelf Life	The maximum shelf life for the packaged product is 3 years.

Child Safety and Disposal

The tablets must be stored out of the sight and reach of children.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements, typically by returning it to a pharmacy or designated collection point.